Nordea Investment Management AB Acquires 544,889 Shares of Hologic, Inc. (NASDAQ:HOLX)

Nordea Investment Management AB increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 32.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,213,607 shares of the medical equipment provider's stock after acquiring an additional 544,889 shares during the quarter. Nordea Investment Management AB owned approximately 0.98% of Hologic worth $159,911,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Caprock Group LLC purchased a new stake in Hologic during the second quarter worth about $432,000. Quest Partners LLC raised its holdings in shares of Hologic by 56.1% in the 2nd quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider's stock worth $3,081,000 after purchasing an additional 14,914 shares during the period. Prudential PLC lifted its stake in Hologic by 79.9% in the second quarter. Prudential PLC now owns 62,677 shares of the medical equipment provider's stock valued at $4,654,000 after purchasing an additional 27,839 shares during the last quarter. Wedbush Securities Inc. grew its holdings in Hologic by 48.6% during the second quarter. Wedbush Securities Inc. now owns 4,760 shares of the medical equipment provider's stock valued at $353,000 after purchasing an additional 1,556 shares during the period. Finally, Choreo LLC purchased a new stake in Hologic in the second quarter worth $393,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $1.08 during trading hours on Tuesday, reaching $72.69. 1,790,566 shares of the stock traded hands, compared to its average volume of 1,819,042. The company's 50-day simple moving average is $76.42 and its two-hundred day simple moving average is $78.55. The company has a market capitalization of $16.50 billion, a P/E ratio of 21.83, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. Hologic, Inc. has a 52-week low of $70.36 and a 52-week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the firm posted $0.89 earnings per share. The business's revenue was up 4.5% compared to the same quarter last year. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.75% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Raymond James increased their price target on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Royal Bank of Canada lifted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Leerink Partners reduced their price objective on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Finally, Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 5th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.